- Home
- PHGE vs CNSP Comparison
PHGE vs CNSP Comparison
Compare PHGE & CNSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PHGE | CNSP |
|---|---|---|
| Founded | 2015 | 2017 |
| Country | United States | United States |
| Employees | 20 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.9M | 7.3M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | PHGE | CNSP |
|---|---|---|
| Price | $0.52 | $4.53 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | N/A | ★ $20.00 |
| AVG Volume (30 Days) | ★ 9.5M | 26.6K |
| Earning Date | 05-15-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 8.03 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.25 | $0.73 |
| 52 Week High | $8.50 | $10.59 |
Technical Indicators
Market Signals| Indicator | PHGE | CNSP |
|---|---|---|
| Relative Strength Index (RSI) | 35.78 | 46.43 |
| Support Level | $0.49 | $4.50 |
| Resistance Level | $0.60 | $5.61 |
| Average True Range (ATR) | 0.11 | 0.31 |
| MACD | 0.00 | -0.10 |
| Stochastic Oscillator | 0.02 | 19.05 |
Price Performance
Historical ComparisonAbout PHGE BiomX Inc. COmmon Stock
BiomX Inc is a company focused on acquiring and further developing technologies that identify, track, and counter physical threats across defense, security, critical infrastructure, and first-response sectors. The Company's portfolio is built around the growing need for earlier and more accurate threat detection, particularly as UAVs and other autonomous systems play a larger role in defense and homeland security.
About CNSP CNS Pharmaceuticals Inc.
CNS Pharmaceuticals Inc is a biotechnology company focused on developing therapies for serious diseases in neurology and oncology. The company is building a high-value pipeline for neurology and oncology indications. Its new corporate includes pivoting from a singular focus on glioblastoma multiforme and exploring out-licensing opportunities for its legacy assets, TPI 287 and Berubicin.